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Clinical trial design and evidence-based outcomes in the study
of liver diseasesq
Jennifer M. Croswell*, Barnett S. Kramer
National Institutes of Health, Oﬃce of Disease Prevention, 6100 Executive Blvd, Suite 2B-03 Bethesda, MD 20892, USACurrent medical training often does not include the formal study of trial design, forcing clinicians to acquire this knowl-
edge independently. This article reviews the foundational elements of clinical trial design. An overarching hierarchy of clin-
ical evidence is introduced, and the relative strengths and limitations of the major types of study designs are discussed. A
corollary to the hierarchy of evidence in trial designs is proposed for trial outcomes: the ‘‘pyramid of endpoints.” This pyr-
amid represents a spectrum of outcomes from tangible health events to intermediate markers with no direct physical impact
on an individual. The potential advantages and diﬃculties inherent in the use of surrogate endpoints for ﬁnal health out-
comes are explored. Randomized controlled trials utilizing ‘‘hard” clinical endpoints are advocated as the most eﬃcient
and reliable way to directly assess the beneﬁts and harms of a therapy; however, using a case study of treatments for hepa-
tocellular carcinoma, we highlight the challenges that can complicate even the highest levels of evidence. All trials have a
‘‘signal-to-noise” ratio – this review emphasizes the need for careful and deliberate consideration of the potential limita-
tions of every study, and provides basic tools to assist the practitioner in identifying common pitfalls of clinical trials.
Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
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The Scottish philosopher David Hume once wrote,
‘‘A wise man proportions his belief to the evidence”
[1]. Unfortunately, clinical training programs are often
deﬁcient in formal education on the fundamental princi-
ples of epidemiology and trial design [2]. Practitioners
are often left to independently develop the critical skill
set of analyzing and interpreting the quality of scientiﬁc
evidence. In an era of increasingly demanding clinical
workloads, coupled with an overwhelming amount of
medical literature of heterogeneous quality, it can be
challenging to sort out exactly what evidence is truly
worthy of one’s attention. This article will provide a0168-8278 Published by Elsevier B .V .on behalf of the European Association
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E-mail address: croswellj@od.nih.gov (J.M. Croswell).framework for understanding the basic elements of clin-
ical trial design and analysis, and will also explore spe-
ciﬁc issues related to hepatocellular carcinoma that
demonstrate some of the more complex, subtle consider-
ations accompanying clinical research designs.2. Questions to ask about medical research: passing the
‘‘clarity test
When interpreting the results of a clinical trial, there
are several basic questions to consider that have over-
arching implications for judging the quality and applica-
bility of that trial. Surprisingly, published medical
research articles frequently fail one or more of the crite-
ria that make up this ‘‘clarity test” (see Table 1).
2.1. What is the exposure and what is the outcome?
It may seem obvious that one needs to have a clear
deﬁnition of the intervention under study and thefor the Study of the Liver .Open access under CC BY-NC-ND license.
Table 1
The ‘‘clarity test” for medical research.
1. What is the exposure and what is the outcome?
2. How certain is it that the exposure actually causes the outcome?
3. How big is the observed eﬀect?
4. How important is the outcome?
5. To whom does the study apply?
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pret a trial. However, there are subtleties in the choice of
both of these elements that can have a large impact on
the ultimate utility of a study, but can be overlooked
when reporting a trial. These factors will be discussed
in detail throughout this article.
2.2. How certain is it that the exposure actually causes the
outcome?
This question gets to the heart of study design, by
highlighting the distinction between an association
between an intervention and an outcome versus a causal
relationship. It also addresses what is known as the inter-
nal validity of a study. Only experimental (i.e., random-
ized controlled) studies can directly establish a causal
relationship between an intervention and an outcome.Target 
population(s) Intermed
Harms of treatmen
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1
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A
Fig. 1. Panel (A) demonstrates a generic analytic framework for medical inter
and intermediate and ﬁnal outcomes under investigation. It demonstrates the di
for a given treatment may be evaluated. Panel (B) provides an example of how a
case, the use of chemotherapy for people with hepatocellular carcinoma. AdapObservational studies may provide good evidence of
an association between an exposure and an outcome.
But if practical (and ethical), the association should then
be tested in a more formal experimental setting to con-
ﬁrm causality.
2.3. How big is the observed eﬀect? and, how important is
the outcome?
It is critical to understand the clinical value and lim-
itations of the chosen outcome(s). For example, is the
outcome of interest an intermediate or surrogate marker
for a ‘‘hard” clinical endpoint? If so, has the surrogate
been validated as a reliable substitute for the ﬁnal end-
point? Is the outcome a composite measure of several
endpoints of varying clinical signiﬁcance? These choices
can obfuscate the conclusions one can or should derive
from a study. Additionally, the value one should ascribe
to an observed eﬀect size is directly related to the choice
of endpoint: a large, seemingly impressive change in a
laboratory value may not be as ultimately meaningful
as a more modest eﬀect on a more tangible endpoint
such as death. It is also important to pay attention to
the manner in which the eﬀect size is expressed – that
is, in relative versus absolute terms – because use of rel-Health 
outcomesiate endpoints
t
3
Decreased 
mortalityor shrinkage
1
3
ventions. An analytic framework makes explicit the population, therapy,
rect and indirect steps by which the overall balance of beneﬁts and harms
n analytic framework might be utilized for a speciﬁc medical issue: in this
ted from Ref. [3]. Used with permission.
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true impact of an intervention. Finally, statistical signif-
icance should not be confused with clinical importance.
Especially in large trials, statistically signiﬁcant diﬀer-
ences may be clinically trivial.
2.4. To whom does it apply?
This question speaks to the generalizability of the
ﬁndings, or the external validity of the study. As will
be discussed later, this is particularly key in clinical stud-
ies of hepatocellular carcinoma, as patients with co-
existing cirrhosis or liver failure (e.g., Childs-Pugh class
B and C) can suﬀer complications from these underlying
conditions that interfere with accurate evaluation of an
intervention’s true eﬃcacy. The balance of beneﬁts and
harms for a given intervention may reverse when mov-
ing from a population of Childs-Pugh class A patients
to B or C patients.Randomized 
Controlled Double 
Blind Studies
Ideas, Opinions
Case Series
Case Control Studies
Randomized
Controlled Studies
Case Reports
Cohort Studies
Fig. 2. The pyramid of evidence represents a general hierarchy of
preferred clinical study designs. As one moves up the pyramid, the
potential for bias is reduced. The pyramid graphically represents that
non-experimental research designs outnumber randomized controlled
trials. Adapted from SUNY Downstate’s evidence-based medicine
course. Used with permission.3. Avoiding mental shortcuts: the analytic framework
Amore formalized method by which one can consider
the salient elements of a clinical trial is termed an analytic
framework, or causal pathway. An analytic framework is a
diagram that presents an explicit representation of the
chain of logic necessary to demonstrate the eﬃcacy of
an intervention on a given outcome [3]. It graphically lays
out each step used to evaluate the overall balance of risks
and beneﬁts associated with a given intervention. As can
be seen in Fig. 1, the analytic framework forces one to
specify the study’s target population, key intervention,
intermediate and ﬁnal health outcomes of interest, and
any potential harms (e.g., toxicities, adverse events) asso-
ciated with the use of the intervention.Most importantly,
the framework highlights the distinction between direct
and indirect proof of eﬃcacy.
If a high-quality randomized, controlled study
directly demonstrates the impact of the intervention on
changes in ﬁnal health outcomes (represented by path
1), this is suﬃcient evidence to establish a causal connec-
tion. However, frequently, this information is lacking.
In this case, the analytic framework provides a visual
representation of the indirect linkages between interven-
tion and desired health outcome (paths 2 and 3). We can
determine where a given study ﬁts along the indirect
causal pathway, and, thus, have a clear depiction of
which critical step(s) in the pathway have not yet been
addressed. Finally, path 4 represents the harms of the
intervention that need to be weighed against any beneﬁts
it has been shown to provide. Thus, the framework
draws attention to the areas where mental shortcuts
would be apt to occur; it illuminates any remaining gaps
in the evidence chain that would preclude drawing a reli-
able conclusion about the intervention.4. The pyramid of evidence
There is a general hierarchy of study designs in med-
ical literature that can be represented as a pyramid (see
Fig. 2). At the base of the pyramid are the lowest forms
of evidence for proving the eﬃcacy of an intervention –
expert opinion and uncontrolled case reports – and at
the top are the highest – double-blind, randomized, con-
trolled studies. The conceit of a pyramid is particularly
helpful because it demonstrates that although the pre-
ponderance of clinical evidence is comprised of non-
experimental study designs, the results from one well-
done randomized controlled trial may overturn an entire
body of observational ﬁndings. A case in point was the
Women’s Health Initiative, a randomized trial that over-
turned assumptions that routine hormone treatment of
postmenopausal women would protect them against
heart disease – an assumption based on a large number
of observational studies [4]. This is because the random-
ized controlled trial is the best tool available to eliminate
bias; as such, it is the most sure we can ever be that any
eﬀect we observe from an intervention is real. It is
important to stress that not all randomized controlled
trials are performed well. The internal validity may be
poor. Thus, careful review of the trial’s methods, as well
as application of the ‘‘clarity test,” are of course
required before acceptance of any study’s conclusions.5. Major types of clinical studies
At the base of the clinical trial hierarchy (following
expert opinion, which is a state of mind rather than a
study design) is the case report. A case report is an
observational study that describes ﬁndings from a single
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ison group. Case reports often portray a ‘‘ﬁrst-of-its-
kind” intervention with optimistic results. They may
oﬀer important clinical insights, but they can also be
misleading. A 2006 letter to the editor in Digestive Dis-
eases and Sciences by Harmanci et al. provides a good
example of a case report. This correspondence described
the case of a 17-year-old girl with Wilson’s disease tak-
ing zinc and D-penicillamine who presented with an
acute hemolytic crisis and impending liver failure.
Within 24 h of admission, the patient’s status declined
to the point where she was evaluated for emergent liver
transplantation. Concurrently, she received 7 days of
plasma exchange treatment, during which her hemoglo-
bin, bilirubin, and INR normalized, her mental status
stabilized, and she was discharged home. The authors
concluded, ‘‘For our patient the treatment of plasma
exchange has prevented liver transplantation. . .. Our
report suggests that. . .early initiation of plasma
exchange can be a very eﬀective modality in reducing
mortality and even preventing orthotopic liver trans-
plantation” [5].
The next level on the pyramid of evidence is the case
series. Uncontrolled case series are basically a group of
case reports, in which the patients all receive the same
intervention; as with a case report, there is no control
group. The study population is often ill-deﬁned. Most
case series are not consecutive (inviting strong selection
bias) or population-based (impeding generalizability).
Here is an example of a case series: investigators at Penn
State University reported on 5 patients with chronic
hepatitis C unresponsive to other therapies treated with
amatadine and ribavirin for an average of 44 months.
These patients were chosen from a pool of 60 partici-
pants of a shorter-term trial of the same therapy; they
were given the opportunity to continue the treatment
because they had ALT normalization, the ability to tol-
erate the treatment without adverse reactions, and a
high level of compliance. At the end of the study, all 5
had improvements in ALT, hepatitis C virus RNA,
and liver histology. One patient had a ﬂare of hepatitis
after treatment discontinuation that resolved with re-ini-
tiation of the therapy. The authors felt this was ‘‘provoc-
ative data on the long-term use of ribavirin and
amatadine in the HCV non-responder. The dramatic
response to retreatment of our main case cannot be
overlooked” [6].
How sure are we that these conclusions are valid?
That is, what are the major limitations of these study
designs? First, in both cases, there is no control group.
We cannot compare the outcome of the girl with Wil-
son’s disease to that of a similar patient who did not
receive plasma exchange therapy, nor can we evaluate
how patients with refractory chronic hepatitis C that
were not treated with amatadine and ribavirin faired.
The importance of such a comparison can be summa-rized by the following anecdote: during world war II,
in the aftermath of the London blitz, rescue workers
were digging in the rubble of an apartment house blown
up in the air raid. They came across a dazed but
unharmed old man lying stark naked in a bathtub. He
was surprised but glad to see help had arrived, and
exclaimed, ‘‘The most extraordinary thing just hap-
pened. I had ﬁnished taking my bath. But when I pulled
the drain plug, the entire house blew up!” [7]. Clearly,
the man could not have known what would have hap-
pened had he not pulled the plug.
It can be easy (and tempting!) to confuse a temporal
relationship with a causal one. Thus, the diﬃculty with
inferring causality from a sequence of events lacking a
control group is that there is no way to know what
would have happened in the absence of the intervention,
and thus, no way to be certain that the intervention was
actually the factor responsible for the observed out-
come. The second limitation of these study designs is
that they are so prone to powerful biases – a point we
shall return to shortly.
One study design that attempts to redress the lack of
a comparator group in observational studies is the case
series with historical controls. This is a study in which
past experience is used as a comparison group for the
cases. In this situation, both the cases and the historical
controls have the same disease, but the primary inter-
vention (and often many other things) has changed over
time. For example, an early investigation into the utility
of hemodialysis for encephalopathy caused by fulminant
hepatic failure compared 39 patients in liver failure trea-
ted by dialysis between 1974 and 1977 with a group of
117 similar patients treated at the same institution ﬁve
years earlier. Dialysis was not available at the hospital
during this previous time period, so the historical con-
trols received conservative intensive care without extra-
corporeal assistance. The authors found that 17 of 39
patients (43.6%) fully regained consciousness after
hemodialysis versus 26 of 117 (22.2%) persons receiving
previous conservative intensive care. The authors cau-
tiously concluded that these were ‘‘hopeful” results [8].
The authors were restrained in their enthusiasm
regarding the results. This is because while there was a
group that did not receive the intervention to compare
results to, the primary diﬃculty with employing a con-
trol population from the past is that it is impossible to
be certain that the group is suﬃciently similar to the cur-
rent intervention population to make a valid compari-
son. Many variables besides the discovery of the
intervention might also have changed over time in the
population: for example, other ancillary therapies in
use to treat the condition, the underlying health status
of the patients, and so on. Therefore, even though there
was an observed diﬀerence between the cases and the
historical controls, it remains unclear whether that
change was truly a result of the intervention, or actually
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intervening years.
One can at least partially avoid this limitation by uti-
lizing a control population from the same time period
and same population: this is the case-control study.
For example, in 1981, MacMahon et al. performed a
case-control study investigating potential exposures
leading to pancreatic cancer [9]. The cases were 369
patients with histologically-conﬁrmed pancreatic cancer;
the controls were 644 concurrently hospitalized patients
being seen by the same attending physicians caring for
the cases. A startling association between coﬀee con-
sumption and incidence of pancreatic cancer was found,
with the relative risk 2.7 times that of controls for per-
sons that drank 3 or more cups per day (95% CI, 1.6–
4.7). Given the prevalence of coﬀee consumption in
the general population, and the high mortality rates
associated with pancreatic cancer, these ﬁndings gener-
ated intense medical and media interest at that time –
as well as beverage-switching behavior. However,
twenty-ﬁve years later, there are no warning labels on
cans of Folgers identifying coﬀee as a carcinogenic sub-
stance. Furthermore, when the authors attempted to
replicate the ﬁndings of this study, they failed to observe
any association between coﬀee consumption and pancre-
atic cancer [10]. What could explain this?
To their credit, MacMahon et al attempted to answer
this question.[11] They carefully scrutinized the charac-
teristics of both the case and the control populations,
and found the answer. In a case-control study, as in
all controlled studies, one attempts to compare two pop-
ulations that are as similar as possible on all known vari-
ables except the one of interest: whether they received
the exposure. In this case, the investigators attempted
to match the two study populations by utilizing controls
that were also sick enough to be in the hospital (but not
because of pancreatic cancer) and were roughly identical
in age, sex distribution, smoking habits, and so on.
However, the controls had been seen by the same
attending physicians as the cases with pancreatic cancer
– that is, gastroenterologists. It became apparent that a
number of the controls had mainly been hospitalized for
conditions such as gastric ulcer and esophagitis. One of
the ﬁrst methods of symptom management these indi-
viduals had been taught by the physicians was to avoid
beverages containing caﬀeine – especially coﬀee.
Thus, the real explanation for the observed associa-
tion between pancreatic cancer and coﬀee consumption
was not a causal relationship between the exposure
and the outcome, but a third, unrecognized factor that
travelled with the populations under investigation. This
created a spurious relationship between the exposure
and disease. This is the deﬁnition of a confounding vari-
able. Confounding is a concern in any observational
study, because it is most likely to occur when someone’s
choice – be it a participant or an investigator – deter-mines who is exposed versus unexposed, rather than
chance. In this example, ‘‘hard-wired” bias was intro-
duced by the use of a control population that avoided
the exposure of interest. There are often fundamental
diﬀerences between populations that are chosen/choose
to receive a medical intervention versus those that do
not, and these innate diﬀerences can silently drive the
results of a study and fool the investigator into believing
a casual relationship exists where it does not.
As an additional example, let us return to the case
series of ribavirin and amatadine therapy for refractory
chronic hepatitis C and reevaluate the criteria by which
the study population was chosen. This trial was a con-
tinuation of a shorter study of the same intervention;
the long-term participants were a small subset of the ori-
ginal trial population, chosen on the basis on their
favorable response to the treatment regimen, their abil-
ity to tolerate the drugs without toxic eﬀects, and their
high compliance with their clinical care regimens [6]. It
is therefore not altogether surprising that this highly
restricted group continued to do better than expected
of the general chronic hepatitis C population, many of
whom may have been too ill to adhere to advised treat-
ments or may not have responded to the therapy. These
patients may also have not started out with normal ALT
levels and might not have been as tolerant of the drugs’
associated toxicities; they may have been generally less
healthy overall. While the results might indeed appear
‘‘provocative” and ‘‘dramatic,” it is impossible to be cer-
tain if they are, in fact, a product of the therapy alone,
or, perhaps more likely, a product of the favorable clin-
ical proﬁle of the participants. The situation also invites
selective reporting and publication bias. Had the ﬁve
patients not done so well, it is unlikely the report would
have seen the light of day.
This issue of confounding explains why even the
cohort study, although considered the highest level of
observational evidence, still falls short of the ‘‘gold stan-
dard” of the randomized controlled trial. A high-quality
cohort study is typically a large, population-based, pro-
spective investigation that compares a group with a spe-
ciﬁc exposure to one not exposed. It diﬀers from the
randomized controlled trial in that it is not a chance
or random event whether a given participant receives
the intervention, but the choice of either the investigator
or the participant him/herself. Therefore, the potential
for inequalities between the exposed and control popula-
tions has not been excluded, and as such, it cannot be
fully established whether the observed relationship
between the exposure and the outcome is a causal or
spurious association. As a gastroenterologist once dryly
observed, non-experimental studies are ‘‘considered
guilty of bias and erroneous results until proven inno-
cent [12];” when designing and interpreting studies,
one should aim for the highest possible level of evidence
upon which to base clinical decisions.
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endpoints
Just as a hierarchy exists for study designs, there is
also one for trial outcomes. Fig. 3 depicts this ‘‘pyramid
of endpoints,” which extends the spectrum from the
most tangible and clinically important outcome (all-
cause mortality), to an outcome with the least direct
physical impact upon an individual (a risk factor
change). For example, let us examine the disease course
for hepatitis B. A change in a risk factor might be an
increase in the use of a needle exchange program in illicit
drug users. Better test results could include a reduction
in ALT or hepatitis B virus DNA levels. The next step
up could be symptomatic chronic hepatitis B. Complica-
tions of disease would include the development of
decompensated liver failure. Disease-speciﬁc mortality
would be represented by death from hepatitis B-induced
liver failure. Finally, there is death from any cause. It is
clear that as we move up through the hierarchy, the out-
comes take on increasingly tangible importance for the
individual patient.
One might question why a distinction is made
between disease-speciﬁc and overall mortality; further-
more, one might question why overall mortality is given
ascendancy over disease-speciﬁc death, given that a ther-
apy is usually intended to only prevent the morbidity or
mortality associated with a single disease process. The
answer is that overall mortality is the least subject to
investigator bias. Attributing a cause of death is not
an entirely objective process – knowledge of the patient’s
various health conditions and comorbidities can
strongly inﬂuence the ﬁnal decision. Dead versus alive,
on the other hand, tends to be a more straightforward
decision.Fig. 3. The pyramid of endpoints represents a generally preferred
hierarchy of study outcomes, going from those with the least clinical
impact to the greatest import. It is often easier to obtain endpoints from
lower down in the pyramid, as they occur with greater frequency in a
population; however, they are less deﬁnitive in establishing the ultimate
clinical utility of a given intervention.Just as with the pyramid of evidence, it is also appar-
ent that outcomes lower down in the hierarchy – those
with less immediate physical import–occur with greater
frequency. One of the logistical challenges of choosing
‘‘hard” clinical endpoints for trials is that they may
require extensive time, money, and personnel commit-
ments. Death may take many years to occur, and is a
far less common event than changes in lab values; there-
fore, utilizing this endpoint can extend the length and
expense of a trial, and can require a large study popula-
tion to discern an eﬀect. For this reason, surrogate end-
points have become increasingly popular choices in
clinical trial design. A surrogate endpoint is a non-
health outcome or biomarker that is used to draw a con-
clusion about the eﬀect of an intervention on a health
outcome observed later in time. It is used as a substitute
for a clinically meaningful endpoint; i.e., one that
directly reﬂects how a patient feels, functions or sur-
vives. The changes a therapy eﬀects on a surrogate are
presumed to fully predict the changes that therapy
would have on the ‘‘hard” endpoint. Thus, although
necessary, it is not suﬃcient for the surrogate to simply
be correlated with the ﬁnal outcome to be considered a
valid and reliable predictor of that endpoint. A validated
surrogate endpoint is one that yields the same inference
about the eﬀect of the treatment as the health outcome
[13].
The most frequently cited potential advantage of sur-
rogate endpoints in clinical trials has already been men-
tioned: they could permit shorter, more eﬃcient trials.
However, there are serious challenges accompanying
their use that must be weighed and considered. As men-
tioned, surrogates occur with greater frequency than
ﬁnal health outcomes. While this is an advantage in
terms of study power (as a diﬀerence in outcomes may
be observed using a smaller sample size), it may also
generate misleading ﬁndings – or ‘‘noise” – since there
is not a 1:1 ratio between the appearance of the surro-
gate and progression to the actual health outcome.
For example, in the case of colorectal cancer, it is
accepted that some colonic adenomas are precursors
to malignancy. However, the majority of adenomatous
polyps will not progress to cancer [14]; since the overlap
between the surrogate and the ﬁnal outcome of interest
is not perfectly aligned, interventions which are highly
eﬀective in preventing or treating all polyps could poten-
tially give a distorted (over)estimate of the intervention’s
true eﬃcacy on the ‘‘hard” health outcome. For exam-
ple, an intervention could conceivably be eﬀective only
against polyps that are not destined to progress to
cancer.
There is another pitfall to be cognizant of when eval-
uating the use of surrogate endpoints. Even validated
surrogates only predict for a single health outcome,
but many (if not most) interventions have more than
one eﬀect upon the human body. The art of medicine
Fig. 4. Challenges to surrogate endpoint use: missed harms.
This highlights one of the major limitations of the use of surrogate
endpoints in clinical studies. Although the trial in this case achieved the
surrogate endpoint of ‘‘beneﬁt,” and was therefore stopped, it provided no
information about important harms that developed after the surrogate
outcome had been obtained. Thus, use of the surrogate endpoint in this
situation provided an overall incorrect picture of the relative balance of
beneﬁts and risks, as it gave no indication of the adverse events that
accrued later in time. From Ref. [17]. Used with permission.
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ative risks and beneﬁts of a therapy for an individual.
This caveat is therefore most critical when considering
the intervention’s potential to cause adverse events. As
demonstrated in Fig. 4, one of the diﬃculties in utilizing
a surrogate endpoint is that it can only provide informa-
tion up until the point that observation ceases (that is, at
the point where surrogate beneﬁt has been established
and the trial is ended). However, the harms of an inter-
vention may have a delayed onset of presentation, and if
they manifest themselves after the point in time when
surrogate eﬀects have been reached, the negative eﬀects
of the treatment will not be apparent in the trial. Some
adverse events are signiﬁcant enough that the total risk-
beneﬁt proﬁle of a given intervention may tip in the
wrong direction; a short trial employing a surrogate
endpoint may not detect this, and may therefore provide
a qualitatively wrong answer about a therapy.
Although this discussion may appear to be merely an
academic exercise or a theoretical postulation of harm,
there are numerous examples in medical history that
demonstrate the misleading potential of surrogate end-Table 2
Examples of discordance between surrogate endpoints and health outcomes.
Intervention Eﬀect on surrogate e
Postmenopausal estrogen + progestin [4] # Cholesterol
# LDL
" HDL
Encainide, ﬂecainide [18] # Cardiac arrhythmia
Low fat diet [19] # Colonic polyps
Intensive blood sugar control with
antiglycemic agents [20]
# HA1C <6.4%
Torcetrapib [21] " HDLpoints. A classic example is – once again – that of post-
menopausal hormone therapy and heart disease.
Multiple studies demonstrated that postmenopausal
estrogen and progestin had favorable eﬀects upon a
woman’s lipid proﬁle: HDL levels rose, and LDL and
total cholesterol levels consistently dropped. Previous
experience with statin therapy had shown that modify-
ing these lab values in a favorable direction resulted in
a positive impact on cardiac event rates. As a result,
the medical community presumed that since hormonal
therapy achieved similar eﬀects on these ‘‘proven” surro-
gates, it would be beneﬁcial in preventing women’s heart
disease. However, when tested in a randomized con-
trolled setting with cardiac events – and not merely the
lipid proﬁle – as the study’s primary endpoint, postmen-
opausal hormone therapy did not reduce heart attacks,
and in fact, showed a trend towards increasing cardiac
events compared with placebo [4].
This example reveals several key limitations of surro-
gate endpoints. The ﬁrst we have already mentioned: a
surrogate outcome can only predict a single health out-
come, and if harms occur after that endpoint has been
reached, a study utilizing the surrogate will provide no
information about those long-term adverse eﬀects. Sec-
ondly, it illustrates that even if a surrogate has been
identiﬁed as useful for one intervention (in this case,
statins), it does not necessarily follow that the surrogate
is valid for other therapies (e.g., hormone replacement).
Although, like statins, hormone therapy did have an
impact on an individual’s lipid proﬁle, it also had a sec-
ondary, competing eﬀect: it increased hemostasis. This
placed women at increased risk for thrombi, occlusive
events, and resulting myocardial infarction; these events
were common and severe enough to overcome any ben-
eﬁt gained by the changes in cholesterol levels. The sur-
rogate endpoint only provided half of the story, with
unfortunate results. While the Women’s Health Initia-
tive study is perhaps the most famous example of an
exposed discordance between a surrogate and an ulti-
mate health outcome, it is not the only one. Table 2 pre-
sents several examples of unexpected contradictions that
have been discovered between proposed surrogates and
their ﬁnal clinical endpoints.ndpoint [17] Eﬀect on ﬁnal health outcome
" Coronary heart disease
s (PVCs) " Sudden cardiac death
$ Incidence of colon cancer
" Death from macrovascular complications
of diabetes (cardiovascular deaths)
" Heart failure, death
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We will now narrow the focus from overarching prin-
ciples of clinical study design to speciﬁc challenges in
liver disease: speciﬁcally, the unique issues encountered
when choosing endpoints for hepatocellular carcinoma
therapies. There is an extensive list of potential out-
comes one might utilize in the study of new treatments
for liver cancer; Table 3 describes several of them. Just
as was previously suggested in the pyramid of endpoints,
overall survival (time from random assignment until
death) is the most important and objective outcome.
Although the pyramid indicates that cancer-speciﬁc
survival should be the next best choice – that is, the time
from random assignment until death from liver cancer –
in the case of hepatocellular carcinoma, there are several
unexpected diﬃculties associated with this endpoint
which must be considered. The endpoint is obviously
of biologic importance, as the therapies under investiga-
tion are disease-speciﬁc (i.e., targeted chemotherapy);
however, one must remember that in this population
death often occurs from concomitant liver failure. When
evaluating the cause of death for patients that are Child-
Pugh class B or C, it can be challenging to sort out
whether the death was speciﬁcally a result of the tumor,
underlying cirrhosis, or even treatment-related toxicity
[15].
Oncology is a ‘‘game of millimeters”: the advantage
gained in life expectancy by a new therapy compared
to standard of care is often as little as weeks or months.
The major issue associated with these intercurrent
causes of mortality is that they can obscure real (but
small) diﬀerences in treatment eﬀect between the new
intervention and the control, as they can generate imbal-
ances of inaccurately classiﬁed deaths in either trial arm.
Thus, promising new therapies might be abandoned pre-
maturely, or ineﬀective therapies embraced. Even
‘‘hard” clinical outcomes near the top of the pyramid
of endpoints may, in fact, be subject to biases.
Time to symptomatic progression (time from random-
ization to deterioration of symptoms as assessed in a
standardized fashion) correlates best with the next step
down on the pyramid, as it attempts to capture a tangi-
ble physical endpoint (symptoms of the disease experi-
enced by the individual). However, once again, there
are unique considerations in the case of hepatocellular
carcinoma that make this choice of outcome less reliable
in therapeutic trials. Time to symptomatic progression
will, in theory, capture both deterioration in quality of
life as well as any drug-related toxicities that are experi-
enced. However, in Childs-Pugh B and C class patients,
cirrhosis can again obscure the true diﬀerentiation of
health impairments resulting from the tumor as opposed
to those caused by liver failure. It has proven so diﬃcult
to accurately ascribe symptoms to one disease processversus the other that there are currently no validated
tools or questionnaires to measure quality of life in
hepatocellular carcinoma, and thus, no reliable and
standardized way to assess this outcome in clinical trials
[15]. Therefore, although quality of life is of critical
importance to patients, time to symptomatic progres-
sion is not currently considered a ﬁrst-line endpoint in
trials of hepatocellular carcinoma therapy.
Regulatory bodies such as the Food and Drug
Administration frequently accept progression-free sur-
vival (a composite endpoint of disease-speciﬁc death
and/or evidence of radiological progression of a tumor)
as an acceptable surrogate endpoint for an oncology
trial when fast-tracking new drug approvals; in other
solid tumors, it may represent a reasonable approach.
However, hepatocellular carcinoma again presents a
special challenge. The vulnerability of this population
to concomitant liver failure remains an important
impediment to accurate evaluation: Just as with dis-
ease-speciﬁc survival, progression-free survival is prone
to inaccurate attribution of the cause of death. Sec-
ondly, the utilization of radiologic progression of a
tumor as an endpoint is vulnerable to a type of time
bias. This endpoint requires frequent repeated measure-
ments equally applied in both study arms to ensure that
the progression is captured at its true temporal onset,
since the outcome is by deﬁnition not associated with
external signs. If the interval between measurements
extends for too long or is applied at diﬀerent intervals,
real diﬀerences between the treatment and control arms
can be missed, or spurious diﬀerences introduced. Thus,
as each individual element of this composite endpoint is
potentially unreliable, extreme caution is advised when
evaluating trials that have employed progression-free
survival in the treatment of hepatocellular carcinoma.
Another indirect surrogate outcome frequently uti-
lized in oncology trials is disease-free survival (a compos-
ite endpoint of time from randomization to disease-
speciﬁc death and/or evidence of radiological recurrence
of a tumor). Disease-free survival – as a composite of
several bias-prone outcomes – suﬀers from the same lim-
itations as progression-free survival.
This case study of hepatocellular carcinoma demon-
strates some of the diﬃculties inherent not only in the
use of surrogate endpoints, but even ‘‘harder” clinical
outcomes like symptomatic disease and death due to a
speciﬁc cause. It emphasizes the importance of going
back to the ‘‘clarity test,” as well as the need for a care-
ful and deliberate consideration of potential limitations,
for every study one evaluates.8. Conclusion
All trials have a ‘‘signal-to-noise” ratio; the trick is to
be able to correctly interpret the ﬁnal balance for a given
Table 3
Potential endpoints in clinical trials in hepatocellular carcinoma.
 Overall survival: Time from randomization until death from any cause. Most objective of any outcome as binary choice of dead versus alive is least
subject to observer bias
 Cancer-speciﬁc survival: Time from randomization until death from heptaocellular carcinoma. Subject to incorrect attribution of cause of death due
to concomitant cirrhosis/liver failure
 Time to symptomatic progression: Time from randomization until occurrence of disease-related symptoms as assessed in a standardized manner.
Subject to incorrect attribution of cause of symptoms due to concomitant cirrhosis/liver failure
 Progression-free survival: A composite endpoint of time from randomization until radiological progression of tumor or death. Subject to incorrect
attribution of cause of death due to concomitant cirrhosis/liver failure as well as incorrect capture of timing of radiological progression of disease
 Disease-free survival: A composite endpoint of time from randomization until either radiological recurrence of tumor or death. Subject to incorrect
attribution of cause of death due to concomitant cirrhosis/liver failure as well as incorrect capture of timing of radiological recurrence of disease
Adapted from Ref. [15]. Used with permission.
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robust and reliable conclusion: these are given general
rankings within the pyramids of evidence and endpoints.
Constructing an analytic framework can also help to
highlight – and thereby avoid – heuristic overenthusiasm
and blunt epistemologic hubris. Be wary of uncontrolled
trials, surrogate endpoints, and studies that permit the
investigator or participant (rather than chance) to
choose an exposure or intervention: all of these are
prone to biases that can generate a seemingly compel-
ling, but qualitatively wrong result. Randomized con-
trolled trials utilizing ‘‘hard” clinical endpoints are the
most eﬃcient and reliable way to directly assess the ben-
eﬁts and harms of a therapy; however, even these are not
infallible. When interpreting a clinical study, one cannot
do better than to follow the advice of physicist Richard
Feynman, who told a stadium of Cal-Tech graduates to
pursue:
A kind of scientiﬁc integrity, a principle of scientiﬁc
thought that corresponds to a kind of utter honesty –
a kind of leaning over backwards. . .. This kind of care
not to fool yourself. . .. You should [consider] every-
thing that you think might make [an experiment] inva-
lid – not only what you think is right about it: other
causes that could possibly explain [the] results; and
things you thought of that you’ve eliminated. . .. Details
that could throw doubt on your interpretation must be
given, if you know them. You must do the best you
can – if you know anything at all wrong, or possibly
wrong – to explain it [16].
It is through this ‘‘care not to fool ourselves” – and
the careful and deliberate application of the highest lev-
els of evidence to clinical decision-making – that real
advances in medical care continue to be made.Acknowledgements
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